✦ LIBER ✦

P100 A multicenter study of docetaxel/cyclophosphamide combination as adjuvant therapy for node negative breast cancer – JECBC04 STUDY

✍ Scribed by T. Tabei; K. Inoue; K. Suemasu; H. Takei; N. Yamamoto; N. Sato; T. Asaga; Y. Yanagita; J. Ando; M. Kurosumi

Book ID: 114316013
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 48 KB
Volume: 16
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(07)70160-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

0143 First efficacy report for China TAX

0143 First efficacy report for China TAX 619 study: Docetaxel in combination with anthracycline and cyclophosphamide or docetaxel followed by anthracycline and cyclophosphamide in adjuvant therapy for operable node positive breast cancer

✍ Z. Shen; G. Liu; Z. Shao; S. Wang; B. Zhang; Z. Jiang; P. He 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Toxicity of Dose-Dense Docetaxel Followe

Toxicity of Dose-Dense Docetaxel Followed by Doxorubicin with Cyclophosphamide as Adjuvant Therapy for Breast Cancer in a Phase II Study

✍ Rosemary Lambert-Falls; Susan Modugno 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 110 KB

Phase III Trial Comparing Doxorubicin Pl

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

✍ Jones, S. E.; Savin, M. A.; Holmes, F. A.; O'Shaughnessy, J. A.; Blum, J. L.; Vu 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 372 KB

Phase I study of docetaxel in combinatio

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer

✍ Vasey, P A; Roché, H; Bisset, D; Terret, C; Vernillet, L; Riva, A; Ramazeilles, 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 110 KB

0142 Feasibility study of fluorouracil/e

0142 Feasibility study of fluorouracil/epirubicin/cyclophosphamide (FEC75) followed by docetaxel (DOC) as adjuvant chemotherapy in Japanese patients with node positive breast cancer

✍ Y. Rai; M. Tanaka; M. Mitsuyama; T. Uga; S. Tanaka; K. Nanba; H. Furusawa; K. Mu 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

A multicenter, phase II study of epirubi

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

✍ Aogi, Kenjiro; Saeki, Toshiaki; Nakamura, Seigo; Kashiwaba, Masahiro; Sato, Nobu 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 329 KB